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Graft failure (GF) is life-threatening complication of allogeneic
transplant (Allo-T). Long-term outcomes of interventions used to
treat this complication have not been extensively studied. We
retrospectively reviewed the long-term survival after GF occurring
at the M.D. Anderson Cancer Center from 1990–2000. Allo-T
recipients were included if they had GF for any of the following
reasons 1) Primary GF (PGF) if pts failed to achieve an ANC
500/l for 3 consecutive days by day 28 post transplant if bone
marrow (BM) or peripheral blood (PBPCs) were the stem cell
source, or 42 days for cord blood (CB); 2) Primary GF with
autologous reconstitution (PGF-AR) if patients recovered hema-
topoiesis without evidence of donor cell engraftment; or 3) Sec-
ondary GF (SGF) if there was a decrease in ANC levels to
500/l
for 3 consecutive days after having achieved engraftment without
disease progression. 68 pts were identiﬁed out of a total of 1750
(4%) allografts performed during that time period. Median age was
37 yrs (range, 4–75); diagnosis included 22 pts with CML or other
myeloproliferative disorders, 27 with acute leukemia, 17 with lym-
phoma or CLL, and 2 with aplastic anemia. 31 pts received cells
from a related donor (15 mismatched in at least 1 allele) while 37
received cells from an unrelated donor. 36 pts received BM, 29
received PB, and 3 received CB. 29 pts had PGF, 9 pts had
PGF-AR and 30 pts had SGF. The 1 and 5 yr overall survival (OS)
for all pts was 31% and 15%. The 1 yr and 5 yr OS for each group
were: PGF-29%/18% PGF-AR 55%/11% and SGF 26%/13%.
The following Table 1 shows the 1 yr and 5 yr survival rates of pts
according to the intervention received. The most common causes
of death were GF (18%) and engraftment but death from infection
(27%) and recurrent/persistent disease (41%). We conclude that
pts who experience GF post allogeneic transplantation can be
successfully treated with a variety of interventions, however, death
from other causes is common. Our data suggest that harvesting
autologous cells for back-up in pts undergoing Allo-T procedures
with high risk of GF is warranted.
Outcomes According to Therapy for GF
None
Growth
Factors
Auto
Back Up
Retrans-
plant
Same Donor
Allo
Back Up
Retrans-
plant
Different
Donor
N 9 19 10 14 9 3
OS @ 1/5 yrs 33%/0% 29%/17% 60%/40% 21%/7% 8%/8% 60%/33%
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OPPORTUNISTIC INFECTIONS ARE THE MAJOR CAUSE OF MORTALITY
AFTER NONMYELOABLATIVE UNRELATED BONE MARROW TRANS-
PLANTATION WITH ALEMTUZUMAB, FLUDARABINE AND MELPHALAN
Carroll, M.P.; BuchBarker, D.; Schwartz, R.; Agha, M.E.; Tompkins,
C.; Baileys, K.; O’Connell, K.; Donnenberg, A.D.; Yeager, A.M. Uni-
versity of Pittsburgh Cancer Institute, Pittsburgh, PA.
Nonmyeloablative (NM) allogeneic (allo) hematopoietic cell
transplantation (HCT) may be effective in patients (pts) at high
risk for morbidity and mortality after conventional myeloablative
HCT. We report the outcome of NM bone marrow transplanta-
tion (BMT) from HLA-matched volunteer unrelated donors
(VUDs) in 14 pts (median age 45 yr; range, 19–58) with relapsed
and/or refractory hematologic malignancies (1 ALL, 3 AML, 3
MDS/AML, 3 Hodgkin’s disease, 2 multiple myeloma, 2 NHL).
Thirteen pts had previous autologous (10 pts) or allo (3 pts) HCT.
The NM regimen included alemtuzumab (20 mg/day 5, days8
through 4), ﬂudarabine (30 mg/m2/day  5, days 7 through
3) and melphalan (140 mg/m2 on day 2), as described by
Kottaridis PD et al, Blood 2000;96:2419 and Chakraverty R et al,
Blood 2002;99:1071. Two pts had primary graft failure (actuarial
probability 16.4%; 95% conﬁdence interval [CI] 0–37.6%). In the
12 evaluable pts, median times to ANC0.5 109/L and platelets
20  109/L were 15 (range, 9–41) and 21 days (range, 15–41),
respectively, after NMBMT. Two pts developed grade I or grade
II acute graft-versus-host disease (GVHD) at 19 and 76 days,
respectively, after NMBMT. The actuarial probability of grade II
or greater GVHD is 9.1% (95% CI 0–26.2%). Two pts developed
extensive chronic GVHD, and one of these pts died with chronic
GVHD-associated pulmonary failure 267 days after NMBMT.
Five pts developed cytomegalovirus (CMV) reactivation, and one
of these pts died with CMV infection at 122 days after NMBMT.
Six pts died with other infections at a median of 74 days (range,
52–209) after NMBMT: 2 adenovirus (1 associated with graft
failure), 2 toxoplasmosis, 1 Aspergillus (associated with graft fail-
ure), and 1 Pseudomonas (associated with chronic GVHD). Actuarial
nonrelapse mortality (NRM) is 60.0% (95% CI 32.6–87.4%), and
infection-associated mortality is 50.0% (95% CI 23.7–76.3%).
Three pts relapsed at 181, 182 and 202 days, respectively, after
NMBMT; actuarial relapse rate is 37.5% (95% CI 4.0–71.0%).
Three pts are alive in remission at 235, 255 and 914 days,
respectively, after NMBMT; actuarial event-free survival (EFS) is
14.3% (95% CI 0–37.4%). Opportunistic infection is the major
cause of NRM and poor EFS in pts with high-risk hematologic
malignancies who undergo VUD NMBMT after alemtuzumab,
ﬂudarabine and melphalan. Efforts to improve immune reconsti-
tution and infection prophylaxis after NMBMT with this regimen
are warranted.
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CALCULATING IV BUSULFAN (IVBU) DOSE USING BODY SURFACE AREA
PREDICTS MEASURED DRUG EXPOSURE MORE ACCURATELY THAN
DOSING IN MG/KG BUT DOES NOT ELIMINATE THE NEED FOR PHAR-
MACOKINETICS (PK) TO OBTAIN DOSING PRECISION
Nance, A.G.; Vaughan, W.P.; Wang, W.; Salzman, D.E. UAB School
of Medicine, Birmingham, AL.
Bu has been shown to be an effective chemotherapeutic agent
against a variety of hematologic diseases when used in high dose
preparative regimens for auto and allo hematopoietic stem cell
transplantation (HSCT), but variation in area under the curve
(AUC) above or below the target range is associated with increased
risk of toxicity or relapse. ivBu minimizes intrapatient variability,
but interpatient variability remains a signiﬁcant problem. The
initial goal of our study was to determine the ability of a test dose
to predict later ivBu levels. Patients are given the ﬁrst of 16 2-hr
infusions of ivBu 48 hours prior to the beginning of the remaining
15 doses given q 6 h. Doses 2–15 are adjusted to achieve a target
AUC based on ﬁrst dose PK. The PK study is performed using a
5-sample limited sampling strategy and a single compartment, ﬁrst
order elimination model in WinNonlin. Using this strategy, more
than 80% of patients achieve an AUC within 10% of the target.
However, due to the expense and time involved in drawing, pro-
cessing, and calculating ivBu levels after a test dose, we sought to
determine if ivBu doses based on any speciﬁc body metric or metric
based formula (BSA) could accurately predict ivBu AUC. Fifty-one
adult patients (aged 18 to 69) from May 2003 to May 2004 receiv-
ing an ivBu containing preparative regimen for allo or auto HSCT
for HD, NHL, AML, ALL, or CML were dosed per the above test
dose strategy. All were given a test dose equal to 0.8 mg per kg for
an average adult weight (70 kg) for a target AUC of 1250 M  min
and proportionately lower doses for lower targets. Using simple
linear regression analysis comparing AUC achieved with dose
given, we sought to determine whether the ﬁxed dose given recal-
culated in mg/m2 (using 3 different formulas), or mg/kg body
weight (actual, ideal, or adjusted ideal) was the best predictor of
AUC achieved. In this comparison mg/m2 yielded an R2 value of
0.58, while the best R2 value using mg/kg was 0.50. Although BSA
predicted for AUC somewhat better than weight alone, neither is
adequate to replace busulfan PK levels at present. In the future we
will look at other factors, which in conjunction with body metrics
may inﬂuence ivBu AUC predictability, including race, gender,
age, BUN, creatinine, ALT, SGOT, and history of hepatic injury
or hepatic risk history. Multivariate linear regression analysis will
be used to determine the best dosing algorithm.
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